#361 Advanced Lipidology

<div>Lipids Update 2022: Cardiovascular Risk Reduction and New Medications on the Horizon with Erin Michos, MD<br> <br> <strong>Show description: </strong><br> Ready to take the next step in management of your patient with hyperlipidemia? Dr. Erin Michos (<a href="https://twitter.com/erinmichos">@erinmichos</a>) returns to give us a lesson in Advanced Lipidology. She updates us on what new medications we can use for those difficult to treat lipids and what medications are on the horizon.<br> <br> <strong>Unfortunately, this episode will not be available for CME. You can claim free CME for other episodes at </strong><a href="http://curbsiders.vcuhealth.org"><strong><a href="http://curbsiders.vcuhealth.org">curbsiders.vcuhealth.org</a></strong></a><strong>!</strong><br> <br> <a href="https://thecurbsiders.com/episode-list">Episodes</a> | <a href="https://audioboom.com/channels/5034728.rss">Subscribe</a> | <a href="https://open.spotify.com/show/3SKlzOLxyztvA1BkJfnf67">Spotify</a> | <a href="https://www.teepublic.com/user/kashlakmemorial">Swag!</a> | <a href="https://thecurbsiders.com/top-picks">Top Picks</a> | <a href="https://thecurbsiders.com/knowledgefood">Mailing List</a> | <a href="mailto:askcurbsiders@gmail.com">askcurbsiders@gmail.com</a> | <a href="http://curbsiders.vcuhealth.org">Free CME!</a><br> <strong><br> Show Segments<br> </strong><br> </div> <ul> <li>Intro, Getting to know Dr. Erin Michos, Pick of the Week</li> <li>Patient Case, Digging into ASCVD Risk </li> <li>Coronary artery calcium scoring - why it’s important</li> <li>What are “Risk Enhancing Factors”?</li> <li>Biomarker testing, what is the significance of Lip a and how can we use it to drive management?</li> <li>Introduction to PCSK9 inhibitors</li> <li>More than just statins - other LDL-lowering medications</li> <li>siRNAs, ASOs - Pelacarsen and more</li> <li>Apollo Trial regarding Pelacarsen</li> <li>Importance of Family History</li> <li>What to do if maxed out on a statin or statin intolerance - Ezetimibe, PCSK9 inhibitors, MAB therapies,